News - Amgen, Sensipar

Filter

Current filters:

AmgenSensipar

Popular Filters

Routine cinacalcet for end stage kidney disease not warranted

01-05-2013

Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and…

AmgenBiotechnologycinacalcetNephrology and HepatologyPharmaceuticalResearchSensipar

FDA suspends pediatric trial of Amgen's Sensipar after patient death

27-02-2013

The US Food and Drug Administration revealed yesterday that it has stopped all pediatric clinical trials…

AmgenBiotechnologyRegulationResearchSensipar

Amgen 4th-qtr net profit plunges 16% but sales up; gets boost from fiscal cliff legislation

24-01-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest biotechnology firm, posted financials after markets…

AmgenBiotechnologyFinancialNorth AmericaPricingSensipar

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients

11-06-2012

Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

Back to top